Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:48:09 06/02/2026 GMT			5-day change	1st Jan Change
104.31 ^CAD	0.00%		-2.94%	-5.54%

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT

Highlights

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-08	Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share	RE
01-06	Bright Minds Biosciences Launches US$100 Million Public Offering	MT
01-06	Bright Minds Biosciences Launches $100 Million Public Offering	MT
01-06	Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies	CI
12-23	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
11-06	Bright Minds Biosciences Inc. Initiates New Prader-Willi Syndrome Program	CI
04/09/25	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model	CI
14/08/25	Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
16/05/25	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
13/05/25	Bright Minds Biosciences Inc. Announces Positive Findings from Its Dba/2 Mouse Model Study Evaluating BMB-101	CI
13/02/25	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024	CI
05/02/25	Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders	RE
23/01/25	Piper Sandler Initiates Bright Minds Biosciences at Overweight	MT
10/01/25	Cantor Fitzgerald Initiates Bright Minds Biosciences With Overweight Rating	MT
10/01/25	HC Wainwright Initiates Bright Minds Biosciences With Buy Rating, $85 Price Target	MT
31/12/24	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2024	CI
26/11/24	Baird Initiates Bright Minds Biosciences at Outperform	MT
21/10/24	Bright Minds Biosciences and Firefly Neuroscience to Collaborate to Provide Full Analysis of the Electroencephalogram Data	CI
21/10/24	Bright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise	MT
18/10/24	Sector Update: Health Care Stocks Advance Late Afternoon	MT
18/10/24	Top Midday Gainers	MT
18/10/24	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
16/10/24	Bright Minds Biosciences Says BMB-201 Had Similar Efficacy to Morphine in Preclinical Pain Models	MT
16/10/24	Bright Minds Biosciences Inc. Announces Positive Data from the Preclinical Testing of BMB-201	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Highlights

Filters